MAC Pulmonary Disease is a lung infection caused by nontuberculous mycobacteria (NTM). It commonly affects people with weakened immune systems or pre-existing lung conditions such as bronchiectasis or COPD.
New Possibilities in Treating MAC PD
MAC Pulmonary Disease is a serious lung infection caused by a group of bacteria known as nontuberculous mycobacteria (NTM). It typically affects individuals with weakened immune systems or underlying lung conditions, leading to symptoms like persistent cough, fatigue, shortness of breath, and weight loss. Because MAC PD can be resistant to standard treatments, managing the condition can be especially challenging.
A current clinical trial is exploring a potential new treatment for individuals with NTM Pulmonary Disease. This study aims to evaluate how well the treatment works in reducing the presence of the bacteria, while also assessing how safe and tolerable it is for participants. Taking part in this research may offer access to new care possibilities and help advance better options for those affected by this difficult condition.
Current Status
Not Recruiting
Study Count
01
Frequently Asked
Questions
What is the purpose of this clinical trial?
The trial is evaluating a potential new treatment to see how effectively it reduces the bacteria causing NTM-PD and how safe and tolerable it is for participants.
Why should I consider participating in this study?
You may gain access to an investigational treatment not yet available through standard care and contribute to research that could improve future treatment options for others with MAC PD.
We’re Here When You’re Ready
Contact us to learn more about clinical trials or
how to get involved.
Contact Us Today
And 99+ others
Have tried Lucida Clinical Trial
Have tried Lucida Clinical Trial
